TOP > 外国特許検索 > CHIMERIC ANTIGEN RECEPTOR GENE-MODIFIED LYMPHOCYTE HAVING CYTOCIDAL EFFECT

CHIMERIC ANTIGEN RECEPTOR GENE-MODIFIED LYMPHOCYTE HAVING CYTOCIDAL EFFECT NEW

外国特許コード F180009508
整理番号 (S2017-0170-N0)
掲載日 2018年11月2日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2017JP043729
国際公開番号 WO 2018110374
国際出願日 平成29年12月6日(2017.12.6)
国際公開日 平成30年6月21日(2018.6.21)
優先権データ
  • 特願2016-242054 (2016.12.14) JP
発明の名称 (英語) CHIMERIC ANTIGEN RECEPTOR GENE-MODIFIED LYMPHOCYTE HAVING CYTOCIDAL EFFECT NEW
発明の概要(英語) The present invention addresses the problem of providing a strategy for therapy in a solid tumor area and a means useful for that purpose in order to further advance the clinical application of CAR therapy. A genetically modified lymphocyte that expresses a chimeric antigen receptor having an ephrinB2 extracellular domain at an antigen recognition site is prepared.
従来技術、競合技術の概要(英語) BACKGROUND ART
Cancer patient's tumor immune system in order to restore, a cytotoxic T cell (CTL) with respect to the T-cell receptor (TCR) is a genetic addition, tumor cells directly and selectively recognized CTL, anti-tumor effect (CAR) chimeric genes that T cell antigen receptor (CAR-T therapy) treatment has been developed in recent years (for example see Non-Patent Document 1).CAR is a protein that specifically recognizes the tumor antigen (usually an antibody variable region in which a single amino acid sequence of a modified single-chain antibody (scFv) is used) to the terminal N, T cell receptor protein C ζ chain has a generic name for the terminal side.T cells express CAR (CAR-T cells) is, in the extracellular domain and after recognition of tumor antigens, that signal is subsequently transmitted into the cells T through ζ chain, to activate the T cells, perforin, such as granzyme cell killing agent to release the anti-tumor effect (for example see Non-Patent Document 1).
CAR-T cells were used as the treatment of cancer in a clinical trial has already been applied.B lymphocytes in blood tumor region CD19 and the positive target tumors and 3 Phase II clinical study is performed first.More specifically, recurrent acute lymphocytic leukemia patient in question, taken from the patient specific CD19 gene CAR T is introduced into the cells, culture, growth in a body of a patient on a result of the infusion device, bone marrow treated with 5 in all of the example obtained by molecular biology remission (for example see Non-Patent Document 2).
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • SHINSHU UNIVERSITY
  • KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION
  • 発明者(英語)
  • Yozo Nakazawa
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JO JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
※ ライセンスをご希望の方、特許の内容に興味を持たれた方は、問合せボタンを押してください。

PAGE TOP

close
close
close
close
close
close